Peptide Knowledge Base · Recovery
BPC-157: what it is, what the evidence says, and its real status
A recovery peptide people take in hope of speeding the healing of tendon, joint, muscle, and gut lining.
Short version: the recovery peptide everyone's talking about, with loud buzz and thin human proof. It's under FDA review, so today it's a waitlist, not something you can legitimately get.
Can you actually get it?
Plain-English verdict: Waitlist.
Regulatory status: Under PCAC review · PCAC · Jul 23–24, 2026.
Not available to prescribe today. Removed from FDA Category 2, but that isn't 'legal to compound,' and it isn't 'available.' It goes before the PCAC on Jul 23–24, 2026; realistic earliest access is late 2026 into 2027.
How does BPC-157 work?
A 15-amino-acid sequence derived from a protein in gastric juice; proposed to support angiogenesis and tissue repair signaling.
What it does — and what it does not do
What it does: Studied for soft-tissue and gut-lining repair support.
What it does not do: It is not a proven cure for any injury, and it is not approved or available to prescribe today.
How honest is the evidence?
Evidence grade D — animal-dominant, fewer than 30 humans, no placebo-controlled efficacy trials. Read our grading methodology for what each grade means.
What we still don't know: Fewer than 30 humans have been studied, with no placebo-controlled efficacy trials. Long-term safety is uncharacterized.
WADA status: Banned (S0).
How it is taken
No established human clinical dosing; research-stage only.
Who should not take it
Not characterized in humans; banned in tested sport (WADA S0). Not for anyone subject to anti-doping rules.
Sources
Sikiric et al., BPC-157 cytoprotection reviews (J Physiol Pharmacol) · FDA PCAC docket, Jul 2026
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.